Answers are grounded in this paper and cite their sources.
A 69-year-old woman with 6 years history of seropositive rheumatoid arthritis (RA) and asymptomatic interstitial lung disease (ILD) began taking adalimumab for ongoing arthritis despite intakes of sulfasalazine and hydroxychloroquine for treatment. ILD progressed noticeably after 10 weeks of starting adalimumab. We discontinued adalimumab and added methylprednisolone 40 mg, and the patient's clinical findings gradually improved. The beneficial and adverse effects of tumor necrosis factor- (TNF-) inhibitors on RA associated ILD are unclear but this case reports adalimumab could abruptly exacerbate known ILD. We emphasize cautions on the use of adalimumab, one of the TNF- inhibitors, in elderly RA patients with preexisting ILD.
No takes yet. Share an insight, caveat, or question.
Park et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: